|120.71||+0.9000||+0.75%||Vol 853.43K||1Y Perf 20.78%|
|Jul 28th, 2021 11:37 DELAYED|
|-0.03 -0.03%||- -|
|Target Price||129.71||Analyst Rating||Strong Buy 1.44|
|Potential %||7.55||Finscreener Ranking||★★★ 50.42|
|Insiders Trans % 3/6/12 mo.||-100/-90/-94||Value Ranking||★★+ 49.16|
|Insiders Value % 3/6/12 mo.||-100/-99/-99||Growth Ranking||★★★★ 61.55|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-99/-99||Income Ranking||★★★ 44.64|
|Market Cap||214.48B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||73.79||Earnings Date||22nd Jul 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||1.01|
|EPS Growth Next 5 Years %||11.70|
|Avg. Weekly Volume||4.60M|
|Avg. Monthly Volume||4.68M|
|Avg. Quarterly Volume||6.23M|
Abbott Laboratories (NYSE: ABT) stock closed at 119.81 per share at the end of the most recent trading day (a 0.24% change compared to the prior day closing price) with a volume of 5.63M shares and market capitalization of 214.48B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 109000 people. Abbott Laboratories CEO is Robert B. Ford.
The one-year performance of Abbott Laboratories stock is 20.78%, while year-to-date (YTD) performance is 9.43%. ABT stock has a five-year performance of 169.54%. Its 52-week range is between 98.67 and 128.54, which gives ABT stock a 52-week price range ratio of 73.79%
Abbott Laboratories currently has a PE ratio of 34.00, a price-to-book (PB) ratio of 6.40, a price-to-sale (PS) ratio of 5.28, a price to cashflow ratio of 22.00, a PEG ratio of 2.32, a ROA of 8.79%, a ROC of 12.29% and a ROE of 19.76%. The company’s profit margin is 15.96%, its EBITDA margin is 27.70%, and its revenue ttm is $40.23 Billion , which makes it $22.64 revenue per share.
Of the last four earnings reports from Abbott Laboratories, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.01 for the next earnings report. Abbott Laboratories’s next earnings report date is -.
The consensus rating of Wall Street analysts for Abbott Laboratories is Strong Buy (1.44), with a target price of $129.71, which is +7.55% compared to the current price. The earnings rating for Abbott Laboratories stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Abbott Laboratories has a dividend yield of 1.51% with a dividend per share of $1.80 and a payout ratio of 57.00%.
Abbott Laboratories has a Buy technical analysis rating based on Technical Indicators (ADX : 9.52, ATR14 : 1.97, CCI20 : 123.20, Chaikin Money Flow : 0.22, MACD : 1.35, Money Flow Index : 44.22, ROC : 0.06, RSI : 59.72, STOCH (14,3) : 73.56, STOCH RSI : 0.38, UO : 62.15, Williams %R : -26.44), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Abbott Laboratories in the last 12-months were: Andrea F. Wainer (Option Excercise at a value of $1 152 000), Andrea F. Wainer (Sold 40 437 shares of value $4 410 287 ), Charles R. Brynelsen (Sold 1 002 shares of value $120 851 ), Christopher J. Scoggins (Option Excercise at a value of $2 017 200), Christopher J. Scoggins (Sold 45 000 shares of value $5 545 800 ), Daniel Gesua Sive Salvadori (Option Excercise at a value of $1 996 513), Daniel Gesua Sive Salvadori (Sold 44 143 shares of value $4 952 396 ), Gregory A. Ahlberg (Sold 1 052 shares of value $126 882 ), Hubert L. Allen (Option Excercise at a value of $7 887 902), Hubert L. Allen (Sold 203 393 shares of value $25 113 251 ), Jared L. Watkin (Option Excercise at a value of $4 832 629), Jared L. Watkin (Sold 95 967 shares of value $11 507 508 ), John F. Ginascol (Option Excercise at a value of $3 111 584), John F. Ginascol (Sold 352 shares of value $42 455 ), John M. Capek (Option Excercise at a value of $1 413 857), John M. Capek (Sold 52 300 shares of value $5 850 278 ), Joseph J. Manning (Option Excercise at a value of $720 000), Joseph J. Manning (Sold 21 880 shares of value $2 687 347 ), Lisa D. Earnhardt (Sold 943 shares of value $113 735 ), Mary K. Moreland (Sold 905 shares of value $113 621 ), Michael D. Dale (Sold 1 475 shares of value $177 900 ), Michelle A. Kumbier (Buy at a value of $249 900), Phebe N. Novakovic (Option Excercise at a value of $513 431), Phebe N. Novakovic (Sold 4 790 shares of value $513 849 ), Randel W. Woodgrift (Sold 3 534 shares of value $387 911 ), Robert E. Funck (Option Excercise at a value of $10 825 395), Robert E. Funck (Sold 249 999 shares of value $27 206 865 ), Roger M. Bird (Sold 7 403 shares of value $818 168 ), William A. Osborn (Option Excercise at a value of $935 991)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.